Astralis, Ltd.
Biotech company reports loss of $0.02 per share
Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
For the 3 months ended September 30, 2004, the company recorded a net loss of $1.6 million to common stockholders, or $0.02 per share. For the 9 months ended September 30, 2004, the company recorded a net loss of $16.0 million to common stockholders, or $0.23 per share.
A one-time preferred stock dividend, related to the conversion into common stock of our Series A Preferred Stock, owned by SkyePharma PLC, accounts for $10.75 million of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Acambis plc
Pharma company releases third quarter 2004 results - Access Pharmaceuticals, Inc.
Pharmaceutical company reports loss of $0.16 per share - Alchemia Limited
Pharma company discusses financial results - Amgen, Inc.
Biotech company announces offer of $2B in two series of senior notes - Antares Pharma, Inc.
Pharmaceutical firm reports loss of $0.06 per share - Australian Cancer Technology
Australian biotech firm confirms fundraising - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
